CA2605161A1 — Dihydrothienopyrimidines for the treatment of inflammatory diseases
Assigned to Boehringer Ingelheim International GmbH · Expires 2006-10-26 · 20y expired
What this patent protects
The invention relates to novel dihydrothienopyrimidines of formula (1) as well as pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of ailments or diseases of the respiratory tract, gastro…
USPTO Abstract
The invention relates to novel dihydrothienopyrimidines of formula (1) as well as pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of ailments or diseases of the respiratory tract, gastrointestinal ailments or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system, or cancer diseases. Also disclosed are pharmaceutical compositions containing the inventive compounds.
Drugs covered by this patent
- Jascayd (NERANDOMILAST) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.